Prices are updated after-hours



nasdaq:RTRX Retrophin, Inc.

RTRX | $ 0% | twitter stocktwits trandingview |
Health Technology

(0% volume)
Earnings Calendar:
http://www.retrophin.com
Sec Filling | Patents | 221 employees

(US) Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.



Drugs
Chenodal (Chenodiol)

add to watch list email alert is off



nasdaq:SOLY Soliton, Inc.

SOLY | $22.58 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (0.0% 1m) (0.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-62.06% volume)
Earnings Calendar:
http://www.soliton.com
Sec Filling | Patents | 10 employees

Soliton, Inc. is a medical development company. It develops healthcare technological devices for medical and cosmetic treatments. The firm’s devices generate planar acoustic waves or shock waves in cosmetic surgical procedures, aesthetic surgical procedures, and dermatology procedures for treatments. The company was founded by Walter V. Klemp & Christopher Capelli on March 27, 2012 and is headquartered in Houston, TX.

aesthetic   treatment  

add to watch list email alert is off



nasdaq:SPEL Spinal Elements Holdings, Inc.

SPEL | $ 0% | twitter stocktwits trandingview |
Health Technology

(0% volume)
Earnings Calendar:

Sec Filling | Patents | n/a employees

Spinal Elements Holdings, Inc. is a medical device company. It engages in designing, developing, manufacturing, and marketing of innovative medical devices used in spinal surgical procedures. The company was founded on March 11, 2016 and is headquartered in Carlsbad, CA.



add to watch list email alert is off



nasdaq:SBPH Spring Bank Pharmaceuticals, Inc.

SBPH | $ 0% | twitter stocktwits trandingview |
Health Technology

(0% volume)
Earnings Calendar:
http://www.springbankpharm.com
Sec Filling | Patents | 30 employees

Spring Bank Pharmaceuticals, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA.

cancer   glass   treatment  

add to watch list email alert is off



nasdaq:SBBP Strongbridge Biopharma plc

SBBP | $2.0 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (0.0% 1m) (-32.7% 1y) (0.0% 2d) (0.0% 3d) (1.5% 7d) (-6.02% volume)
Earnings Calendar:
http://www.strongbridgebio.com
Sec Filling | Patents | 71 employees

(US) Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded on May 26, 2015 and is headquartered in Trevose, PA.

msa  

add to watch list email alert is off



nasdaq:SNBP Sun BioPharma, Inc.

SNBP | $3.44 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1m) (0.0% 1y) (0.0% 7d) (161.81% volume)
Earnings Calendar:
http://www.sunbiopharma.com
Sec Filling | Patents | 5 employees

Sun BioPharma Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The company was founded by Michael Cullen and Thomas Neenan on September 21, 2011 and is headquartered in Waconia, MN.

cancer   pancreatic  

add to watch list email alert is off



nasdaq:SNSS Sunesis Pharmaceuticals, Inc.

SNSS | $13.5 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1m) (0.0% 1y) (0.0% 2d) (153.8% 3d) (0.0% 7d) (-99.11% volume)
Earnings Calendar:
http://www.sunesis.com
Sec Filling | Patents | 24 employees

Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA.

cancer   clinical trials   treatment  

add to watch list email alert is off



nasdaq:TLGT Teligent, Inc.

TLGT | $0.1735 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (-13.9% 1m) (-67.6% 1y) (-13.9% 2d) (-47.9% 3d) (0.0% 7d) (-26.89% volume)
Earnings Calendar:
http://www.teligent.com
Sec Filling | Patents | 252 employees

Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.

brands  

Drugs
Lidocaine 4% Cream (Lidocaine)
ZANTAC (ranitidine hydrochloride)

add to watch list email alert is off



nasdaq:TBIO Translate Bio, Inc.

TBIO | $37.36 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1m) (35.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (131.28% volume)
Earnings Calendar:
http://www.translate.bio
Sec Filling | Patents | 93 employees

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidates include MRT5005 for the treatment of cystic fibrosis; and for the treatment of ornithine transcarbamylase deficiency. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

fibrosis   treatment  

add to watch list email alert is off



nasdaq:UROV Urovant Sciences Ltd.

UROV | $16.24 0% | twitter stocktwits trandingview |
Health Technology

(0.1% 1m) (0.0% 1y) (0.0% 2d) (0.1% 3d) (0.0% 7d) (1161.77% volume)
Earnings Calendar:
http://www.urovant.com
Sec Filling | Patents | n/a employees

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. Its pipeline includes Vibegron (RVT-901) and URO-902. The company was founded on January 27, 2016 and is headquartered in London, the United Kingdom.



add to watch list email alert is off



nasdaq:DRMT Dermavant Sciences Ltd.

DRMT | $ 0% | twitter stocktwits trandingview |
Health Technology

(0% volume)
Earnings Calendar:

Sec Filling | Patents | n/a employees

Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company which focuses on developing and commercializing therapeutics in medical dermatology. The company is developing a pipeline of therapies in medical dermatology and is currently advancing development programs for five product candidates which targets specific unmet needs in two of the immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne. The company was founded on September 28, 2015 and is headquartered in London, the United Kingdom.

dermatitis   acne   atopic dermatitis  

add to watch list email alert is off



nasdaq:DRAD Digirad Corporation

DRAD | $3.59 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar:
http://www.digirad.com
Sec Filling | Patents | 618 employees

Digirad Corp. engages in the provision of healthcare solutions. It operates through the following segments: Diagnostic Services, Mobile Healthcare, Diagnostic Imaging, Building and Construction and Real Estate and Investments. The Diagnostic Services segment offers imaging and monitoring services program for purchasing equipment or outsourcing the procedures to another physician or imaging center. The Mobile Healthcare segment provides contract diagnostic imaging, including computerized tomography, magnetic resonance imaging, positron emission tomography, PET/CT and nuclear medicine and healthcare to hospitals, delivery networks and federal institutions on a long-term contract basis, as well as provisional services to institutions that are in transition. The Diagnostic Imaging segment sells internally developed solid-state gamma cameras, imaging systems and camera maintenance contracts. The Building and Construction segment provides residential and commercial construction projects by manufacturing modular housing units and other products and supplies general contractors with building materials. The Real Estate and Investments segment manages real estate assets and investments. The company was founded in 1997 and is headquartered in Suwanee, GA.

magnetic resonance   pets   diagnostics   housing   construction  

add to watch list email alert is off



nasdaq:EIDX Eidos Therapeutics, Inc.

EIDX | $122.21 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (516.77% volume)
Earnings Calendar:
http://www.eidostx.com
Sec Filling | Patents | 45 employees

Eidos Therapeutics, Inc. focuses on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR). Its product include the AG10, an orally-administered small molecule designed to potently stabilize TTR, suggesting a treatment with the potential to halt the progression of ATTR. The company was founded by Graef Isabella and Alhamadsheh Mamoun on August 6, 2013 and is headquartered in San Francisco, CA.

treatment  

add to watch list email alert is off



nasdaq:EYEG Eyegate Pharmaceuticals, Inc.

EYEG | $1.99 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (0.0% 1m) (-45.3% 1y) (-1.5% 2d) (-1.5% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
http://www.eyegatepharma.com
Sec Filling | Patents | 10 employees

(United States) EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

ocular   eye  

add to watch list email alert is off



nasdaq:FLXN Flexion Therapeutics, Inc.

FLXN | $9.12 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (0.0% 1m) (10.8% 1y) (0.0% 2d) (-0.2% 3d) (0.0% 7d) (352.61% volume)
Earnings Calendar:
http://www.flexiontherapeutics.com
Sec Filling | Patents | 288 employees

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

osteoarthritis   brands   msa   treatment  

Drugs
Zilretta (triamcinolone acetonide extended-release injectable suspension)

add to watch list email alert is off



nasdaq:GNMK GenMark Diagnostics, Inc.

GNMK | $24.04 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
http://www.genmarkdx.com
Sec Filling | Patents | 437 employees

GenMark Diagnostics, Inc. engages in the provision of multiplex molecular diagnostic solutions. Its solutions include ePlex System, eSensor, Electrowetting, and XT-8 System. The company was founded by Jon Faiz Kayyem in 1993 and is headquartered in Carlsbad, CA.

molecular diagnostics   multiplexing   diagnostics  

add to watch list email alert is off



nasdaq:GNCA Genocea Biosciences, Inc.

GNCA | $0.051 | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (-16.1% 1m) (-97.8% 1y) (0.0% 2d) (-15.0% 3d) (0.0% 7d) (-35.74% volume)
Earnings Calendar:
http://www.genocea.com
Sec Filling | Patents | 59 employees

(US) Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

vaccine   cancer   immunotherapy   t-cell   genetic   treatment   ceiling  

add to watch list email alert is off



nasdaq:HJLI Hancock Jaffe Laboratories, Inc.

HJLI | $10.38 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1m) (51.1% 1y) (0.0% 2d) (-2.0% 3d) (0.0% 7d) (-36.73% volume)
Earnings Calendar:
http://www.hancockjaffe.com
Sec Filling | Patents | 12 employees

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include The Bioprosthetic Heart Valve, The CoreoGraft, and The Venous Valve. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

cardiovascular   heart  

add to watch list email alert is off



nasdaq:HTBX Heat Biologics, Inc.

HTBX | $2.38 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (0.0% 1m) (-64.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-60.37% volume)
Earnings Calendar:
http://www.heatbio.com
Sec Filling | Patents | 36 employees

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

cancer   immunotherapy   immunology   t-cell   hepatitis   ceiling  

add to watch list email alert is off



nasdaq:XLRN Acceleron Pharma Inc.

XLRN | $179.68 0% | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (0.0% 1m) (43.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar:
http://www.acceleronpharma.com
Sec Filling | Patents | 237 employees

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

hypertension   anemia   treatment  

add to watch list email alert is off



Your Today's Watch List
Sign in to create a watchlist
Last 48 Hours Insiders Buying
ALTG P 3227 | $9.29 -2.52% 0.0% | twitter stocktwits trandingview |
Distribution Services
| 01:40
SKIL P 30000 | $3.61 -6.96% 2.22% | twitter stocktwits trandingview |
Information
| 23:50
CAMP P 20000 | $4.65 -1.27% 0.86% | twitter stocktwits trandingview |
Electronic Technology
| 16:00